Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Shilpa Medicare Ltd (SHILPAMED)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530549 NSE: SHILPAMED Pharmaceuticals & Drugs | Small Cap | Shilpa Medicare Share Price
₹821.90 14.50 (1.80%)
As on 14-Aug'26 16:59
Shilpa Medicare Ltd (SHILPAMED)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530549 NSE: SHILPAMED Pharmaceuticals & Drugs | Small Cap | Shilpa Medicare Share Price
₹821.90 14.50 (1.80%)
As on 14-Aug'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹16,075 Cr.
Current Price
₹821.9
52-Week Low / High
₹260 / 825
TTM EPS
₹15.2
TTM Sales
₹1,682 Cr.
Book Value per Share
₹137.3
P/E Ratio
54.07
Lower than its 5-year historical median
Industry PE
53.5
Price to Book (P/B)
5.98
Higher than its 5-year historical median
Price to Sales (P/S)
9.55
Higher than its 5-year historical median
EV/EBITDA
34.34
Higher than its 5-year historical median
Dividend Yield
0.06%
Profitability Efficiency
Return on Equity (ROE)
9.82%
Outperforms industry median
Return on Capital Employed (ROCE)
11.43%
Outperforms industry median
Return on Assets (ROA)
6.97%
Operating Profit Margin
23.8%
Net Profit Margin
15.81%
Gross Profit Margin
25.1%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
11.71%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
24.37%
Net Profit Growth (1 Year)
-
210.81%
Asset Quality
Promoter Holding
40.13%
Pledged shares (%) of Promoter's holding (%)
8.73%
Reserves
₹2,667 Cr.
Equity
₹19.6 Cr.
Face Value
₹1
All Time Low / High
₹0.20 / 825.40
Check Before You Invest
Quality
Very GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Strong
Is Shilpa Medicare Ltd a good quality company?
Shilpa Medicare Ltd is a good quality company, based on a consistently good multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Shilpa Medicare Ltd performance compare with that of its Peers?
Revenue growth of Shilpa Medicare Ltd vs industry peers?
Shilpa Medicare Ltd revenue CAGR is 7.22%, compared to the industry median CAGR of 5.75%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Shilpa Medicare Ltd?
Promoters hold 40.13% of the Shilpa Medicare Ltd, with 8.73% of their stake pledged, indicating low pledge risk.
Stock return of Shilpa Medicare Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 11.4% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Shilpa Medicare Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 19.7% | 15.3% | 11.1% | 10.5% | 12.4% | 10.7% | 5.9% | 0.8% | 5.5% | 7% | - |
| Value Creation Index ⓘ | 0.4 | 0.1 | -0.2 | -0.3 | -0.1 | -0.2 | -0.6 | -0.9 | -0.6 | -0.5 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 716 | 779 | 789 | 733 | 908 | 901 | 1,146 | 1,050 | 1,152 | 1,286 | 1,682 |
| Sales YoY Gr. | - | 8.8% | 1.2% | -7% | 23.8% | -0.8% | 27.1% | -8.3% | 9.7% | 11.7% | - |
| Adj EPS ⓘ | 7.2 | 6.5 | 6 | 5.4 | 8.9 | 5.5 | 2.9 | -2.4 | 1.2 | 4.6 | 15.2 |
| YoY Gr. | - | -10% | -7.6% | -10.7% | 65.8% | -38.4% | -46.2% | -182.7% | NA | 276.4% | - |
| BVPS (₹) ⓘ | 41.5 | 61.6 | 66.5 | 73.5 | 81.5 | 90.7 | 105 | 102.7 | 104.2 | 120.8 | 137.3 |
| Adj Net Profit ⓘ | 111 | 104 | 97.7 | 87.3 | 145 | 89 | 51 | -42.1 | 21.3 | 90.6 | 297 |
| Cash Flow from Ops. ⓘ | 129 | 37.5 | 44.9 | 147 | 124 | 46.9 | 105 | 180 | 137 | 132 | - |
| Debt/CF from Ops. ⓘ | 0.7 | 6.4 | 4.3 | 1.3 | 3.1 | 18 | 6.5 | 4.4 | 6.9 | 4.4 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 6.7% | 7.2% | 3.9% | 11.7% | ||||
| Adj EPS ⓘ | -4.8% | -12.2% | 16.3% | 276.4% | ||||
| BVPSⓘ | 12.6% | 8.2% | 4.8% | 15.9% | ||||
| Share Price | 11.4% | 23.6% | 66.1% | 81.3% | ||||
Key Financial Parameters ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 18.7 | 12.8 | 9.4 | 7.7 | 11.4 | 6.3 | 3.1 | -2.3 | 1.2 | 4.3 | 11.8 |
| Op. Profit Mgn % ⓘ | 22.5 | 20.8 | 19.2 | 21.1 | 23.6 | 19.1 | 17.4 | 8.4 | 20.5 | 23.8 | 28.4 |
| Net Profit Mgn % ⓘ | 15 | 12.9 | 12.1 | 11.5 | 15.8 | 9.7 | 4.4 | -3.9 | 1.9 | 7 | 17.7 |
| Debt to Equity ⓘ | 0.1 | 0.2 | 0.2 | 0.2 | 0.3 | 0.6 | 0.4 | 0.5 | 0.5 | 0.3 | - |
| Working Cap Days ⓘ | 158 | 193 | 237 | 266 | 230 | 286 | 280 | 309 | 273 | 270 | 120 |
| Cash Conv. Cycle ⓘ | 59 | 84 | 116 | 141 | 126 | 170 | 165 | 186 | 160 | 164 | 29 |
Valuation of Shilpa Medicare - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 90.41 | 90.41 | 7.90 | 7.92 | 7.92 | 7.92 | 7.92 | 8.73 | 8.73 | 8.73 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 779 | 789 | 733 | 908 | 901 | 1,146 | 1,050 | 1,152 | 1,286 | 1,539 |
| Operating Expenses ⓘ + | 618 | 638 | 579 | 693 | 729 | 948 | 962 | 916 | 980 | 1,158 |
| Operating Profit ⓘ | 162 | 151 | 154 | 215 | 172 | 197 | 88 | 236 | 306 | 381 |
| Operating Profit Margin (%) | 20.7% | 19.2% | 21.0% | 23.6% | 19.1% | 17.2% | 8.4% | 20.5% | 23.8% | 24.8% |
| Other Income ⓘ + | 29 | 33 | 16 | 22 | 40 | 21 | 31 | 17 | 36 | 64 |
| Interest ⓘ | 3 | 3 | 4 | 5 | 22 | 41 | 59 | 92 | 76 | 59 |
| Depreciation ⓘ | 31 | 37 | 42 | 44 | 54 | 80 | 95 | 108 | 113 | 120 |
| Profit Before Tax ⓘ | 146 | 137 | 136 | 188 | 195 | 102 | -38 | 54 | 122 | 295 |
| Tax ⓘ | 42 | 34 | 26 | 33 | 49 | 42 | -7 | 22 | 44 | 52 |
| Profit After Tax | 104 | 103 | 110 | 155 | 146 | 61 | -31 | 32 | 78 | 243 |
| PAT Margin (%) | 13.4% | 13.0% | 14.9% | 17.0% | 16.2% | 5.3% | -2.9% | 2.8% | 6.1% | 15.8% |
| Adjusted EPS (₹) | 6.7 | 6.5 | 6.9 | 9.6 | 9.1 | 3.5 | -1.9 | 1.8 | 4.0 | 12.4 |
| Dividend Payout Ratio (%) | 4.50% | 5.40% | 7.30% | 5.70% | 6.10% | 15.70% | 0% | 0% | 12.50% | 4.80% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 987 | 1,085 | 1,198 | 1,329 | 1,479 | 1,822 | 1,783 | 1,809 | 2,363 | 2,591 | |
| Debt + | 235 | 166 | 168 | 330 | 718 | 557 | 633 | 921 | 539 | 595 | |
| Minority Interest | -3 | -5 | -8 | -8 | -11 | -11 | -9 | -9 | 1 | 0 | |
| Trade Payables | 112 | 104 | 81 | 93 | 77 | 146 | 143 | 174 | 105 | 142 | |
| Others Liabilities ⓘ | 141 | 149 | 172 | 245 | 371 | 362 | 354 | 188 | 290 | 360 | |
| Total Liabilities ⓘ | 1,472 | 1,499 | 1,610 | 1,989 | 2,632 | 2,875 | 2,904 | 3,083 | 3,298 | 3,689 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 492 | 534 | 558 | 650 | 1,111 | 1,342 | 1,368 | 1,385 | 1,418 | 1,593 | |
| CWIP ⓘ | 141 | 210 | 429 | 666 | 541 | 506 | 655 | 719 | 822 | 884 | |
| Investments ⓘ | 253 | 140 | 2 | 10 | 21 | 34 | 43 | 40 | 35 | 58 | |
| Inventories | 190 | 189 | 188 | 226 | 333 | 355 | 320 | 345 | 348 | 367 | |
| Trade Receivables | 171 | 220 | 204 | 247 | 234 | 386 | 324 | 392 | 441 | 519 | |
| Cash Equivalents | 100 | 74 | 95 | 45 | 124 | 34 | 22 | 32 | 29 | 45 | |
| Others Assets ⓘ | 126 | 132 | 135 | 144 | 269 | 218 | 172 | 171 | 206 | 223 | |
| Total Assets ⓘ | 1,472 | 1,499 | 1,610 | 1,989 | 2,632 | 2,875 | 2,904 | 3,083 | 3,298 | 3,689 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 37 | 45 | 147 | 124 | 47 | 105 | 180 | 137 | 132 | 342 |
| Cash Flow From Investing Activity ⓘ + | -262 | -9 | -196 | -290 | -404 | -285 | -233 | -167 | -199 | -326 |
| Cash Flow From Financing Activity ⓘ + | 313 | -61 | 10 | 176 | 436 | 83 | 46 | 47 | 63 | 14 |
| Net Cash Flow ⓘ | 88 | -25 | -39 | 10 | 79 | -98 | -7 | 17 | -4 | 30 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 12.85 | 9.93 | 9.59 | 12.23 | 10.41 | 3.67 | -1.71 | 1.78 | 3.75 | 9.82 |
| ROCE (%) | 15.28 | 11.13 | 10.45 | 12.38 | 10.73 | 5.94 | 0.8 | 5.49 | 6.95 | 11.43 |
| Asset Turnover Ratio | 0.65 | 0.53 | 0.47 | 0.5 | 0.39 | 0.42 | 0.36 | 0.38 | 0.4 | 0.44 |
| PAT to CFO Conversion(x) | 0.36 | 0.44 | 1.34 | 0.8 | 0.32 | 1.72 | N/A | 4.28 | 1.69 | 1.41 |
| Working Capital Days | ||||||||||
| Receivable Days | 69 | 90.20 | 105.50 | 90.60 | 97.30 | 98.80 | 123.50 | 113.50 | 118.20 | 113.80 |
| Inventory Days | 75.50 | 87.30 | 93.70 | 83.20 | 113.30 | 109.70 | 117.30 | 105.40 | 98.30 | 84.80 |
| Payable Days | 107.20 | 110.60 | 131 | 113.90 | 114 | 106 | 126.70 | 146.70 | 128.20 | 101.90 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Shilpa Medicare Ltd FAQs
The current trading price of Shilpa Medicare on 14-Aug-2026 16:59 is ₹821.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 13-Aug-2026 the market cap of Shilpa Medicare stood at ₹16,074.9 Cr
The latest P/E ratio of Shilpa Medicare as of 13-Aug-2026 is 88.01.
The latest P/B ratio of Shilpa Medicare as of 13-Aug-2026 is 5.79.
The 52-week high of Shilpa Medicare is ₹825.4 and the 52-week low is ₹260.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Shilpa Medicare is ₹691 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Shilpa Medicare Ltd is a good quality company.
The key valuation ratios of Shilpa Medicare Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Shilpa Medicare Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Shilpa Medicare Ltd
Shilpa Medicare, established in 1987, has carved a niche for itself in the exceedingly competitive and quality-conscious sphere of pharmaceuticals manufacturing. It produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
The company has earned its spurs as a successful and reliable partner within the pharmaceutical industry. Buyers within the country and from across the borders count on its fast track integrated process development and finely honed expertise of its skilled and experienced personnel. The company is already exporting to USA, Canada, Australia, Japan and European countries viz., Germany, Switzerland, Netherlands, Belgium, Spain, Greece, Cyprus, Italy, United Kingdom etc., South American countries like Mexico, Brazil, Columbia etc, African countries like Kenya, Nigeria and West Indies etc, Asian countries like Singapore, Taiwan, China, Malaysia, Thailand and closer to home to Iran, Egypt, Pakistan and Bangladesh. Shilpa Medicare is synergizing strength through tie-ups for manufacturing products and co-marketing rights, for it believes in working together and sharing success.
Being proactive in approach, the company continually seeks out enquiry’s for development of new products drawing from the extensive knowledge-base of its qualified and experienced people as well as sophisticated facilities.
Product range of the company includes:
Oncology AP's
- Anastrozole
- Bicalutamide
- Carboplatin
- Gemcitabine HCI
- Irinotecan HCl Trihydrate
- Oxaliplatin
- Temozolomide
- Cisplatin
- 5-Fluoro
- Bortezomib
- Capecitabine
- Decarbazine
- Docetaxel
- Gefitinib
- Hydroxy urea
- Imatinib Mesylate
- Lenalidomide
- Letrozole
- Methotrexate
- Thalidomide
- Topotecan HCl
- Zoledronic acid
General APIs
- Ambroxol HCl
- Ticlopidine HCl
- Buflomedil HCl
- Nifedipine
- Lamivudine
- Sildenafil Citrate
- Terfenadine
- Acebrophylline
- Phenylephrine HCl
- Ursodeoxycholic acid
PRODUCTS UNDER DEVELOPMENT (Oncology)
- Bendamustine Cladribine
- Decitabine Disodium Pamidronate
- Epirubicin Exemustane
- Fludarabine Phosphate Idarubicine
- Paclitaxel Pemetrexed
- Lomustine Methotrexate
- Pamidronic acid Tandutinib
NUTRITIONAL SUPPLEMENTS
- Chromium picolinate Chromium polynicotinate
DRUG INTERMEDIATES
- Trans-4-amino cyclohexanol
- 2-Amino-3,5-dibromobenzaldehyde
- 1,3,5-Trimethoxy Benzene
- 1,3,5-Tribromo Benzene
- 7-ethyl camptothecin
- 7-ethyl-10-hydroxy camptothecin
Awards & Achievements:
- Karnataka State Govt. 'Best Enterpreneur Award'.
- Govt. of India 'Best Enterpreneur Award'.
- ‘Star Export House’ Status from Ministry of Commerce and Industry, Govt. of India
- 'cGMP' Certificates from W.H.O. for 20 API's
- 'Best Export Award' from Visvesvaraya Industrial Trade Centre, Bangalore, Govt. of Karnataka, INDIA
- 'Outstanding Industrial Award' from Indian Junior Chamber.
- 'Registration with 'Russian Health Authority' for Ambroxol HCl
- 'Certificate of Suitability' received from EDQM for Ambroxol HCl (R0-CEP 2004-201-Rev 00)
- 'Certificate of Suitability' received from EDQM for Ticlopidine HCl (R0-CEP 2005-004-Rev 00)
- 'Certificate of Suitability' received from EDQM for Carboplatin (R0-CEP 2006-212-Rev 00)
- Patent application on Irinotecan HCl Trihydrate 'An improved process for the preparation of Irinotecan HCl Trihydrate' published as WO2006016203 on date 2006-02-16
- Patent file for Gemcitabine HCl and Anastrozole manufacturing process.
- Filed ASMF/EDMF of Gemcitabine HCl over 21 EU countries
- Filed ASMF/EDMF of Irinotecan HCl Trihydrate HCl over 27 EU countries
- Filed ASMF/EDMF of Oxaliplatin HCl over 11 EU countries
- 'Best District Export Award' received from FKCCI, Bangalore on 16.06.2007
- Korean FDA Approved for Gemcitabine HCl & Ambroxol HCl
- COS received from EDQM for Buflomedil HCl (R0-CEP 2006-080-Rev.00)
- COS received from EDQM for Oxaliplatin EP (R0-CEP 2006-201-Rev.00)
- 'Best District Export Award' received from FKCCI, Bangalore on 20.06.2008.
- COS received from EDQM for Gemcitabine HCl EP (R0-CEP 2006-222-Rev 00)
- 2010 - Shilpa Medicare Limited was granted certificate of GMP Compliance of Manufacturer for Gemcitabine Hydrochloride
- 2012 - Shilpa Medicare Ltd has been conferred First Prize of the National Energy Conservation Award-2012 in the Drugs & Pharmaceuticals Sector from Ministry of Power, New Delhi.
You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
